Valuation: Waverley Pharma Inc.

Market Cap 1.08M 774K 689K 632K 574K 73.11M 1.1M 7.56M 3.03M 38.69M 2.9M 2.84M 123M P/E 2024
-0.57x
P/E 2025 -2.16x
Enterprise Value 4.48M 3.21M 2.86M 2.62M 2.38M 303M 4.58M 31.34M 12.56M 160M 12.04M 11.79M 508M EV / Sales 2024
7.09x
EV / Sales 2025 3.32x
Free-Float
25.1%
Yield 2024 *
-
Yield 2025 -
1 day+100.00%
1 week+100.00%
Current month+100.00%
1 month+100.00%
3 months+33.33%
6 months+100.00%
1 week 0.02
Extreme 0.02
0.02
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.04
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.04
5 years 0.01
Extreme 0.01
0.1
10 years 0.01
Extreme 0.01
0.6
Manager TitleAgeSince
Chief Executive Officer - 01/02/2020
Director of Finance/CFO - 01/01/2020
Director TitleAgeSince
Chairman 79 14/12/2016
Director/Board Member 54 14/12/2016
Director/Board Member - 22/11/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/8/26 Option

Chairman

-10,000,000 18.5185%
24/6/24 Other

Director

0 0%
18/8/21 Other

Chairman

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%+100.00%0.00%-42.86% 774K
+10.00%+4.50%+58.63%+71.20% 66.87B
+0.85%+4.53%+24.41%+102.11% 56.55B
+1.28%+2.64%+14.13%+78.78% 57.2B
+0.46%-5.47%+25.04%+33.77% 43.47B
+2.82%+5.82%+240.96%+801.17% 42.8B
+6.42%+1.18%+22.18%+105.56% 42.95B
+2.79%-3.04%+99.73%+83.47% 32.11B
+5.32%+5.37%+19.12%+52.98% 34.01B
+5.32%+13.43%-39.82%+342.66% 24.13B
Average +13.53%+2.46%+46.44%+162.88% 40.01B
Weighted average by Cap. +4.02%+2.58%+53.38%+170.18%

Financials

2024 2025
Net sales 475K 340K 303K 278K 253K 32.18M 486K 3.33M 1.33M 17.03M 1.28M 1.25M 53.95M 1.35M 967K 861K 790K 718K 91.36M 1.38M 9.44M 3.78M 48.35M 3.63M 3.55M 153M
Net income -947K -678K -604K -554K -504K -64.11M -969K -6.63M -2.66M -33.93M -2.55M -2.49M -107M -499K -358K -319K -292K -266K -33.79M -511K -3.49M -1.4M -17.89M -1.34M -1.31M -56.66M
Net Debt 2.83M 2.03M 1.81M 1.66M 1.51M 192M 2.9M 19.8M 7.94M 101M 7.61M 7.45M 321M 3.4M 2.43M 2.17M 1.99M 1.81M 230M 3.48M 23.78M 9.53M 122M 9.14M 8.94M 386M
Projected Income Statement - Annual - Waverley Pharma Inc.
Logo Waverley Pharma Inc.
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development and commercialization of human therapeutics focused on oncology. It is advancing its PARP-1 pre-clinical development program, which is in the lead optimization stage, in response to the interest in novel PARP-1 inhibitors that demonstrate selective activity against PARP-1 over PARP-2. The lead compound exhibits single-digit nanomolar activity and significant selectivity for PARP-1 over PARP-2, in pre-clinical invitro testing. It has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited (Licensor or RLS) by which the Licensor granted the Company an exclusive territorial license to market and sell capecitabine in the United Kingdom (UK) and Germany as well as a non-exclusive territorial license to market and sell temozolomide in the UK. It also has territorial licenses from RLS to two oncologic drugs, pemetrexed and bortezomib.
Employees
-
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. WAVE Stock